At a glance
ClinicalIndex Comparison Record- ✓Meets DSM-IV criteria for current cocaine dependence
- ✓Cocaine use confirmed by urine toxicology: at least 4 days in prior month OR episodic binges worth at least $200 twice monthly
- ✕Meets DSM-IV criteria for major depression, bipolar disorder, schizophrenia, or any psychotic disorder (except transient psychosis from drug abuse)
- ✕History of seizures in the 2 years prior to enrollment
- ✕History of seizures related to current substance abuse (cocaine, alcohol, or benzodiazepine)
- ✕History of allergic reaction to memantine
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Placebo-Controlled Trial of the Effectiveness of Memantine in Treating Cocaine Dependence
In Brief
A Phase 2 clinical trial evaluating Memantine and placebo for Cocaine-Related Disorders. Completed, enrolled 81 participants across 1 site.
Detailed Summary
Cocaine is one of the most widely abused drugs in the United States. Memantine is a type of drug called an NMDA receptor antagonist. It works by decreasing normal excitement in the brain. NMDA receptor antagonists have shown to reduce cocaine-induced dopamine release in animal models, as well as lessen conditioned cocaine cues. The purpose of this study is to determine the effectiveness of memantine in preventing relapse to cocaine use in cocaine dependent individuals. In addition, this study will determine whether memantine produces better results than a placebo in decreasing cocaine craving, psychological symptoms, functional impairment, and discontinuation of treatment in cocaine dependent individuals.
Study Details
Timeline
Interventions
Memantine
placebo